ArticleTranslational vision science & technology2026
Novel Quantitative OCTA Biomarkers of Choroidal Neovascularization and Associations With Disease Activity and Etiology.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Novel semi-automated system for multi-dimensional analysis of macular neovascularization: quantitative biomarkers and rule-based morphological categorization across OCTA platforms.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Partial Spontaneous Regression of the Late-Onset Choroidal Neovascularization after Full-Thickness Macular Hole Surgery without Anti-VEGF Therapy: A Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to develop a semi-automated optical coherence tomography angiography (OCTA) framework for quantitative morphological assessment of choroidal neovascularization (CNV) to examine associations between quantitative metrics and CNV etiology, activity, and lesion patterns. Methods: This retrospective study analyzed treatment-naïve eyes with neovascular age-related macular degeneration (nAMD), myopic CNV (mCNV), or inflammatory CNV (iCNV). OCTA images were processed with a standardized pipeline combining AngioTool, ImageJ, and custom Python algorithms to extract vascular-network and contour-heterogeneity metrics. Results: Sixty‑six eyes were analyzed (21 with nAMD, 23 with mCNV, and 22 with iCNV). The nAMD lesions were largest and most branched, showing the greatest median vessel area (1.24 mm2), perimeter (8.369 mm), MaxFeret (2.603 mm), MinFeret (1.598 mm), and total vessel length (14.583 mm)-all significantly greater than mCNV (all P < 0.017). The mCNV lesions were compact and regular. The iCNV lesions exhibited pronounced contour irregularity with lowest circularity (0.621) and vertex index (0.843), and highest maximum (0.243 mm) and mean (0.137 mm) depression depths. For activity assessment, a five-parameter model (vessel area, vessel density, total junctions, average depression, and circularity) discriminated active versus inactive CNV with excellent accuracy (area under the curve [AUC] = 0.901). Conclusions: Quantitative OCTA biomarkers distinguish CNV etiologies and activity, providing a noninvasive, objective basis for clinical assessment and individualized treatment planning. Translational Relevance: This study bridges the gap between image processing and clinical practice by validating a quantitative OCTA pipeline sensitive to etiology-specific morphological variations. The resulting multivariate model provides an objective, noninvasive tool for assessing CNV activity. Ultimately, these OCTA biomarkers offer a reproducible method to optimize disease monitoring and guide personalized management of CNV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.